It continues to be a benign week of trading the sector. I think the context matters in that given the underperformance even slow neutral weeks feels worse than it is. We are waiting for that solid move to the upside given how long and far the sector has underperformed. While it is tedious to have […]
The sector feels like it is in a worse place than it actually is. I think the underperformance compared to the broader market is aggravating especially because this have been happening for awhile. All of that disappointment aside, the sector does not seem like it is going to breakdown but of course one worries what […]
Not a great start to the week both in terms of news and trading. I think they are linked in that we had a series of bad news and that is impacting the sector. I do not think any of the news runs the risk of forcing a downside break but certainly it was not […]
A muted start to the morning but hopefully we can build on some of the positive momentum from yesterday. It seems to me that the sector wants to get to that $130 level where it should be some resistance. I think that level is important in the near term but longer term it is that […]
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.